ME01980B - Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat - Google Patents
Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumaratInfo
- Publication number
- ME01980B ME01980B MEP-2014-150A MEP15014A ME01980B ME 01980 B ME01980 B ME 01980B ME P15014 A MEP15014 A ME P15014A ME 01980 B ME01980 B ME 01980B
- Authority
- ME
- Montenegro
- Prior art keywords
- tablet
- layer
- microcrystalline cellulose
- sodium
- rilpivirine
- Prior art date
Links
- 229960002814 rilpivirine Drugs 0.000 title claims 13
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title claims 13
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims 8
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 title claims 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 18
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 14
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 13
- 229960001681 croscarmellose sodium Drugs 0.000 claims 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 13
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 11
- 229960001021 lactose monohydrate Drugs 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 235000019359 magnesium stearate Nutrition 0.000 claims 9
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims 6
- 229960000366 emtricitabine Drugs 0.000 claims 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 6
- 229940068977 polysorbate 20 Drugs 0.000 claims 6
- 239000007916 tablet composition Substances 0.000 claims 5
- 229920000881 Modified starch Polymers 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229960004481 rilpivirine hydrochloride Drugs 0.000 claims 2
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical group Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- -1 dihydroaluminum Chemical compound 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000001433 sodium tartrate Substances 0.000 claims 1
- 229960002167 sodium tartrate Drugs 0.000 claims 1
- 235000011004 sodium tartrates Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (23)
1.Tableta koja sadrži prvi sloj i drugi sloj pri čemu; a) prvi sloj sadrži rilpivirin HCl i suštinski je bez tenofovir dizoproksil fumarata, i pri čemu manje od oko 12.2 masenog procenta prvog sloja je rilpivirin HCl; b) drugi sloj sadrži tenofovir dizoproksil fumarat, i i suštinski je bez rilpivirin HCl-a; i c) tableta dalje sadrži emtricitabin.
2.Tableta zahteva 1 gde prvi sloj ne sadrži emtricitabin.
3.Tableta zahteva 1 ili 2 koja sadrži 27.5 ± 1.4 rng rilpivirin HCl-a.
4.Tableta bilo kog od zahteva 1-3 koja sadrži 200 ± 10.0 mgemtricitabina.
5.Tableta bilo kog od zahteva 1-4 koja sadrži 300 ± 15.0 mgtenofovir dizoproksil fumarata.
6.Tableta bilo kog od zahteva 1-5 gde prvi sloj dalje sadrži jedan ili više rastvarača, sredstva za raspadanje, sredstva za vezivanje, ili lubrikante.
7.Tableta zahteva 6 gde je totalna masa prvog sloja 275 ± 75 mg, pre svega veća od225 mg a posebno je 275 ± 50 mg.
8.Tableta bilo kog od zahteva 1-7 gde prvi sloj sadrži sredstvo za povećanje baznosti koje je prvenstveno izabrano od natrijum kroskarmeloze, kalcijum karbonata, natrijum hidroksida, aluminijum oksida, hidroksida alkalnih metala, hidroksida zemnoalkalnih metala, aluminijum hidroksida, dihidroaluminijuma, natrijum karbonata, amonijum hidroksida, magnezijum karbonata, magnezijum stearata, piperazina, natrijum acetata, natrijum citrata, natrijum tartarata, natrijum maleata, i natrijum sukcinata i njihovih mikstura.
9.Tableta bilo kog od zahteva 1-8 gde prvi sloj sadrži natrijum kroskarmelozu, i polisorbat 20 i posebno sadrži laktozu monohidrat, povidon, natrijum kroskarmelozu, polisorbat 20, mikrokristalnu celulozu, i megnezijum stearat.
10.Tableta bilo kog od zahteva 1-9 gde drugi sloj sadrži mikrokristalnu celulozu i natrijum kroskarmelozu a posebno sadrži laktozu monohidrat, preželatinizirani skrob, mikrokristalnu celulozu, natrijum kroskarmelozu, i magnezijum stearat.
11.Tableta bilo kog od zahteva 1-10 gde je prvi sloj u kontaktu sa drugim slojem.
12.Tableta bilo kog od zahteva 1-10 koja dalje sadrži treći sloj koje je između i koji razdvaja prvi sloj i drugi sloj.
13.Tableta zahteva 12 gde treći sloj sadrži laktozu monohidrat i/ili mikrokristalnu celulozu.
14.Supstanca Jedinica formule za tablete (mg/tableta) Rilpivirin HCl 27.5 Mikrokristalna celuloza 60.0 Laktoza monohidrat 189.8 Povidon 3.3 Polisorbat 20 0.4 Tableta bilo kog od zahteva 1-5 gde je prvi sloj omotač od polimernog filma koji je u kontaktu sa drugim slojem i poželjno potpuno prekriva drugi sloj.
15. Tableta zahteva 2 gde prvi sloj sadrži: Supstanca Jedinica formule za tablete (mg/tableta) Rilpivirin HCl 27.5 ± 1.4 Mikrokristalna celuloza 60.0 ±3 Polisorbat 20 0.4 ± 0.02 Natrijum kroskarmeloza
16.1 ±0.8 a drugi sloj sadrži: Supstanca Jedinica formule za tablete (mg/tableta) Emtricitabin 200 ± 10 Tenofovir dizoproksil fumarat 300 ± 15 Mikrokristalna celuloza 150 ± 7.5 Natrijum kroskarmeloza 60 ±3. ili gde se prvi sloj sastoji od: Supstanca Jedinica formule za tablete (mg/tableta) Natrijum kroskarmeloza 16.1 Magnezijum Stearat 3.0 a drugi sloj se sastoji od: Supstanca Jedinica formule za tablete (mg/tableta) Emtricitabin 200.0 Tenofovir dizoproksil fumarat 300.0 Mikrokristalna celuloza 150.0 Laktoza monohidrat 80.0 Preželatinizirani skrob 50.0 Natrijum kroskarmeloza 60.0 Magnezijum Stearat 10.0. 16. Tableta zahteva 12 gde se prvi sloj sastoji od: Supstanca Jedinica formule za tablete (mg/tableta) Rilpivirin HCl 27.5 Mikrokristalna celuloza 60.0 Laktoza monohidrat 189.8 Povidon 3.3 Polisorbat 20 0.4 Natrijum kroskarmeloza 16.1 Magnezijum Stearat 3.0 drugi sloj se sastoji od: Supstanca Jedinica formule za tablete (mg/tableta) Emtricitabin 200.0 Tenofovir dizoproksil fumarat 300.0 Mikrokristalna celuloza 150.0 Laktoza monohidrat 80.0 Preželatinizirani skrob 50.0 Natrijum kroskarmeloza 60.0 Magnezijum Stearat 10.0 a treći sloj sadrži 150 ± 8.0 mg mikrokristalne celuloze ili laktoza monohidrata, ili njihove miksture.
17.Tableta bilo kog od zahteva 1-13 i 15-16 koja dalje sadrži film omotač koji poželjno sadrži 34 ± 12 mg Opadry II Purple 33G100000.
18.Tableta koja ima prvi sloj koji se satoji od: Supstanca mg Rilpivirin HCl 27.5 Mikrokristalna celuloza 60.0 Laktoza monohidrat 189.8 Povidon 3.3 Polisorbat 20 0.4 Natrijum kroskarmeloza 16.1 Magnezijum Stearat 3.0 Ukupna masa sloja 300.0 adrugi sloj se sastoji od: Supstanca mg Supstanca mg Emtricitabin 200.0 Tenofovir DF 300.0b Mikrokristalna celuloza 150.0 Laktoza monohidrat 80.0 Preželatinizirani skrob 50.0 Natrijum kroskarmeloza 60.0 Magnezijum Stearat 10.0 Ukupna masa sloja 850.0 a omotač se sastoji od: Supstanca mg Opadry II Purple 33G100000 34.5 Ukupna masa tablete 1184.5.
19.Tableta bilo kog od zahteva 1-13 gde najmanje oko 5.4 masenog procenta prvog sloja je natrijum kroskarmeloza i najmanje oko 63.3 masenog procenta prvog sloja je laktoza monohidrat.
20.Tableta bilo kog od zahteva 1-14 gde manje od oko 12 masenog procenta prvog sloja je rilpivirin hidrohloriđ.
21.Tableta zahteva 1 gde prvi sloj sadrži 27.5 ± 1.4 mg rilpivirin hidrohlorida i gde je totalna masa prvog sloja najmanje oko 230 mg.
22.Tableta kao što je opisano u bilo kom od zahteva 1-21 za primenu u profilaktičkom ili terapeutskom tretmanu HIV infekcije, gde rilpivirin AUC (area under the curve-površina ispod krive) koji je postignut primenom kod čoveka uz ishranu nije više od oko 25% veći od rilpivirin AUCkoji je postignut primenom kod čoveka na dijeti ili gde rilpivirin Cmaxkoji je postignut primenom kod čoveka uz ishranu nije više od oko 25% veći od rilpivirin Cmax koji je postignut primenom kod čoveka na dijeti.
23. Tableta kao što je opisano u bilo kom od zahteva 1-21 za primenu profilaktičkom ili terapeutskom tretmanu HIV infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41560010P | 2010-11-19 | 2010-11-19 | |
| EP11791161.0A EP2640362B2 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate |
| PCT/US2011/061515 WO2012068535A1 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01980B true ME01980B (me) | 2015-05-20 |
Family
ID=45094284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-150A ME01980B (me) | 2010-11-19 | 2011-11-18 | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10857102B2 (me) |
| EP (2) | EP2640362B2 (me) |
| JP (2) | JP2014500261A (me) |
| KR (1) | KR101923103B1 (me) |
| CN (2) | CN103491948B (me) |
| AP (1) | AP3816A (me) |
| AR (2) | AR084500A1 (me) |
| AU (3) | AU2011329642B2 (me) |
| BR (1) | BR112013012245B1 (me) |
| CA (1) | CA2818097C (me) |
| CL (1) | CL2013001402A1 (me) |
| CO (1) | CO6761300A2 (me) |
| CR (1) | CR20130293A (me) |
| DK (1) | DK2640362T4 (me) |
| EA (2) | EA201691695A1 (me) |
| EC (2) | ECSP13012700A (me) |
| ES (1) | ES2524408T5 (me) |
| HK (1) | HK1206592A1 (me) |
| HR (1) | HRP20140946T1 (me) |
| IL (1) | IL226300B (me) |
| MA (1) | MA34735B1 (me) |
| ME (1) | ME01980B (me) |
| MX (1) | MX347512B (me) |
| MY (1) | MY185604A (me) |
| NZ (1) | NZ610729A (me) |
| PE (3) | PE20170521A1 (me) |
| PH (1) | PH12013501002A1 (me) |
| PL (1) | PL2640362T5 (me) |
| PT (1) | PT2640362E (me) |
| RS (1) | RS53691B1 (me) |
| SG (3) | SG10201509521WA (me) |
| SM (1) | SMT201400150B (me) |
| TW (1) | TWI556840B (me) |
| UA (1) | UA114075C2 (me) |
| WO (1) | WO2012068535A1 (me) |
| ZA (1) | ZA201304481B (me) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| SG10201509521WA (en) | 2010-11-19 | 2015-12-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| HRP20161696T4 (hr) | 2011-08-16 | 2023-10-13 | Gilead Sciences, Inc. | Tenofovir alafenamid hemifumarat |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| EP2832351A1 (en) * | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multilayer Tablet Formulations Comprising Tenofovir and Entecavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| KR20170003063A (ko) * | 2015-06-30 | 2017-01-09 | 한미약품 주식회사 | 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| SG11201802983TA (en) * | 2015-11-09 | 2018-05-30 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
| US20190060325A1 (en) * | 2016-04-08 | 2019-02-28 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| US10561614B2 (en) * | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
| JP7287906B2 (ja) * | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| JP2022538338A (ja) * | 2019-07-03 | 2022-09-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 |
| CN112137981A (zh) * | 2020-11-02 | 2020-12-29 | 成都晶富医药科技有限公司 | 富马酸丙酚替诺福韦片及其制备工艺 |
| WO2024211882A1 (en) * | 2023-04-07 | 2024-10-10 | Navinta, Llc | Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents |
| CN119174735A (zh) * | 2024-09-03 | 2024-12-24 | 安徽贝克生物制药有限公司 | 一种含利匹韦林的复方片及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ241625A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US20030124186A1 (en) | 2001-11-27 | 2003-07-03 | Hussain Munir A. | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| MXPA05007016A (es) | 2003-01-14 | 2005-09-12 | Gilead Sciences Inc | Composiciones y metodos para terapia antiviral de combinacion. |
| CA2577288C (en) | 2004-09-02 | 2010-11-30 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| ATE508748T1 (de) | 2004-09-02 | 2011-05-15 | Janssen Pharmaceutica Nv | Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril. |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| JP2009511191A (ja) | 2005-10-14 | 2009-03-19 | マイクロドース・テクノロジーズ・インコーポレーテッド | 経口投与剤組合せ型医薬パッケージ法 |
| ATE474560T1 (de) | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| PL3150586T3 (pl) * | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| JP2010527996A (ja) * | 2007-05-22 | 2010-08-19 | ウルティモルフィクス・テクノロジーズ・ベー・フェー | テノホビルジソプロキシル−ヘミフマル酸共結晶 |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| WO2009106960A2 (en) | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| DK2393485T3 (en) | 2009-02-06 | 2015-10-26 | Gilead Sciences Inc | Bilayer COVERING ELVITEGRAVIR, COBICISTAT, emtricitabine and tenofovir |
| PE20120995A1 (es) | 2009-09-21 | 2012-08-01 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| SG10201509521WA (en) | 2010-11-19 | 2015-12-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
-
2011
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 PH PH1/2013/501002A patent/PH12013501002A1/en unknown
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 HR HRP20140946AT patent/HRP20140946T1/hr unknown
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en not_active Ceased
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 RS RS20140668A patent/RS53691B1/sr unknown
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active Active
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
-
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
-
2014
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/en unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
-
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
-
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
-
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
-
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
-
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01980B (me) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat | |
| JP2015131853A5 (me) | ||
| EP3236943A1 (en) | Compositions for ileo-jejunal drug delivery | |
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| JP2006516570A5 (me) | ||
| HRP20190069T1 (hr) | Farmaceutske formulacije koje sadrže ccr3 antagoniste | |
| KR20140101391A (ko) | 심혈관 질환의 치료 방법 | |
| SA515361123B1 (ar) | مستحضر توليفة صيدلانية تشتمل على فيماستاران ورسيوفاستاتين لعلاج مرض القلب الوعائي | |
| EP3041511A2 (en) | Compositions of eltrombopag | |
| JP2020511419A5 (me) | ||
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| CA2927720A1 (en) | Composite formulation comprising tadalafil and amlodipine | |
| JP2019526591A (ja) | ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法 | |
| RU2016106336A (ru) | Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения | |
| JP2008201713A (ja) | フィルムコーティング用組成物 | |
| JP2016104729A (ja) | 湿製錠剤、及び湿製錠剤の製造方法 | |
| WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
| CN104487057A (zh) | 波生坦控释口服制剂 | |
| RU2677649C2 (ru) | Фармацевтические композиции монтелукаста и левоцетиризина | |
| JPWO2022055880A5 (me) | ||
| RU2007125596A (ru) | Комбинированный противотуберкулезный препарат | |
| WO2018091609A1 (en) | Formulation comprising 4-methylpyrazole | |
| KR20120120519A (ko) | 나이아신 및 ＨＭＧ－ＣｏＡ 환원 효소 억제제를 포함하는 복합제제 및 그의 제조방법 | |
| JP2018184382A (ja) | エゼチミブ含有錠剤およびその製法 | |
| JP2018516274A5 (me) |